| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stomach Neoplasms | 116 | 2024 | 2349 | 8.260 |
Why?
|
| Gastrectomy | 54 | 2024 | 480 | 5.040 |
Why?
|
| Peritoneal Neoplasms | 38 | 2024 | 835 | 4.730 |
Why?
|
| Hyperthermia, Induced | 27 | 2024 | 516 | 3.670 |
Why?
|
| Appendiceal Neoplasms | 26 | 2023 | 242 | 3.650 |
Why?
|
| Adenocarcinoma | 73 | 2024 | 7877 | 2.660 |
Why?
|
| Esophagogastric Junction | 20 | 2024 | 559 | 1.890 |
Why?
|
| Laparoscopy | 28 | 2023 | 1288 | 1.850 |
Why?
|
| Cytoreduction Surgical Procedures | 21 | 2024 | 492 | 1.840 |
Why?
|
| Adenocarcinoma, Mucinous | 13 | 2023 | 442 | 1.760 |
Why?
|
| Robotic Surgical Procedures | 8 | 2023 | 527 | 1.660 |
Why?
|
| Pseudomyxoma Peritonei | 6 | 2021 | 37 | 1.400 |
Why?
|
| Lymph Node Excision | 32 | 2024 | 2035 | 1.350 |
Why?
|
| Neoplasm Staging | 68 | 2022 | 13883 | 1.190 |
Why?
|
| Neoadjuvant Therapy | 27 | 2024 | 5156 | 1.150 |
Why?
|
| Melanoma | 58 | 2011 | 5393 | 1.120 |
Why?
|
| Chemoradiotherapy | 13 | 2024 | 2006 | 1.080 |
Why?
|
| Esophageal Neoplasms | 16 | 2024 | 3258 | 1.020 |
Why?
|
| Lymph Nodes | 27 | 2021 | 3037 | 1.020 |
Why?
|
| Mitomycin | 9 | 2020 | 207 | 0.950 |
Why?
|
| Carcinoma, Signet Ring Cell | 8 | 2016 | 173 | 0.940 |
Why?
|
| Skin Neoplasms | 43 | 2011 | 4744 | 0.910 |
Why?
|
| Survival Rate | 54 | 2024 | 12475 | 0.900 |
Why?
|
| Combined Modality Therapy | 41 | 2024 | 9020 | 0.880 |
Why?
|
| Carcinoma | 8 | 2024 | 2602 | 0.790 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 41 | 2024 | 16327 | 0.770 |
Why?
|
| Hospitals, Low-Volume | 2 | 2019 | 56 | 0.770 |
Why?
|
| Surgical Oncology | 1 | 2023 | 208 | 0.750 |
Why?
|
| Humans | 255 | 2024 | 270969 | 0.730 |
Why?
|
| Gastric Stump | 1 | 2020 | 3 | 0.730 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 10 | 2020 | 172 | 0.730 |
Why?
|
| Cecum | 1 | 2020 | 41 | 0.720 |
Why?
|
| Preoperative Care | 15 | 2021 | 1556 | 0.710 |
Why?
|
| Aged | 131 | 2024 | 73018 | 0.690 |
Why?
|
| Middle Aged | 159 | 2024 | 89661 | 0.670 |
Why?
|
| Hospitals, High-Volume | 1 | 2019 | 79 | 0.640 |
Why?
|
| Male | 173 | 2024 | 127769 | 0.630 |
Why?
|
| Lymphatic Metastasis | 39 | 2021 | 4940 | 0.630 |
Why?
|
| Retrospective Studies | 79 | 2024 | 39724 | 0.610 |
Why?
|
| Female | 172 | 2024 | 147624 | 0.590 |
Why?
|
| Catheterization, Central Venous | 7 | 2013 | 364 | 0.580 |
Why?
|
| Prognosis | 55 | 2024 | 22348 | 0.540 |
Why?
|
| Antineoplastic Agents | 25 | 2021 | 14558 | 0.540 |
Why?
|
| Hospital Mortality | 3 | 2019 | 1403 | 0.490 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2020 | 7765 | 0.490 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2017 | 310 | 0.490 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2017 | 1051 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 23 | 2023 | 10282 | 0.470 |
Why?
|
| Follow-Up Studies | 36 | 2024 | 15255 | 0.460 |
Why?
|
| Patient Selection | 4 | 2018 | 2111 | 0.460 |
Why?
|
| Adult | 110 | 2024 | 80872 | 0.450 |
Why?
|
| Postoperative Complications | 11 | 2024 | 5853 | 0.420 |
Why?
|
| Aged, 80 and over | 56 | 2023 | 30845 | 0.400 |
Why?
|
| Radiotherapy, Adjuvant | 11 | 2017 | 2270 | 0.400 |
Why?
|
| Subclavian Vein | 4 | 2000 | 37 | 0.400 |
Why?
|
| Prospective Studies | 30 | 2024 | 13336 | 0.390 |
Why?
|
| Chemotherapy, Adjuvant | 21 | 2018 | 3968 | 0.380 |
Why?
|
| Cisplatin | 15 | 2020 | 2465 | 0.380 |
Why?
|
| Hospitalization | 2 | 2019 | 2220 | 0.360 |
Why?
|
| Abdominal Neoplasms | 4 | 2015 | 242 | 0.350 |
Why?
|
| Treatment Outcome | 46 | 2023 | 34335 | 0.350 |
Why?
|
| Sentinel Lymph Node Biopsy | 12 | 2011 | 1451 | 0.350 |
Why?
|
| Chemoradiotherapy, Adjuvant | 7 | 2020 | 568 | 0.330 |
Why?
|
| Camptothecin | 6 | 2017 | 536 | 0.330 |
Why?
|
| Mesothelioma | 4 | 2021 | 554 | 0.320 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2009 | 730 | 0.310 |
Why?
|
| Peritoneal Lavage | 2 | 2019 | 21 | 0.310 |
Why?
|
| Neoplasms | 9 | 2023 | 15797 | 0.300 |
Why?
|
| Robotics | 2 | 2023 | 366 | 0.300 |
Why?
|
| Colorectal Neoplasms | 8 | 2023 | 3676 | 0.300 |
Why?
|
| Fluorouracil | 12 | 2023 | 1968 | 0.290 |
Why?
|
| Adenofibroma | 1 | 2007 | 20 | 0.290 |
Why?
|
| Perfusion | 3 | 2024 | 298 | 0.290 |
Why?
|
| Organoplatinum Compounds | 7 | 2017 | 705 | 0.280 |
Why?
|
| Appendix | 2 | 2017 | 41 | 0.270 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 1706 | 0.270 |
Why?
|
| Peritoneum | 5 | 2020 | 156 | 0.260 |
Why?
|
| Neutropenia | 2 | 2009 | 987 | 0.250 |
Why?
|
| Infusions, Parenteral | 4 | 2009 | 191 | 0.250 |
Why?
|
| Japan | 2 | 2021 | 227 | 0.240 |
Why?
|
| Disease-Free Survival | 23 | 2021 | 10092 | 0.240 |
Why?
|
| Prealbumin | 1 | 2023 | 37 | 0.230 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2008 | 622 | 0.230 |
Why?
|
| Hospitals | 1 | 2007 | 497 | 0.220 |
Why?
|
| Palliative Care | 4 | 2024 | 2149 | 0.220 |
Why?
|
| Risk Factors | 23 | 2018 | 18036 | 0.220 |
Why?
|
| Neoplasms, Experimental | 1 | 2007 | 750 | 0.220 |
Why?
|
| Ghrelin | 1 | 2023 | 78 | 0.220 |
Why?
|
| Nitrogen | 1 | 2023 | 179 | 0.220 |
Why?
|
| Esophagectomy | 3 | 2023 | 953 | 0.220 |
Why?
|
| Quality of Life | 7 | 2023 | 4737 | 0.210 |
Why?
|
| Pleural Neoplasms | 2 | 2006 | 479 | 0.210 |
Why?
|
| Operating Rooms | 1 | 2023 | 126 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 5 | 2014 | 2487 | 0.200 |
Why?
|
| Texas | 8 | 2021 | 6489 | 0.200 |
Why?
|
| Paclitaxel | 5 | 2020 | 2061 | 0.200 |
Why?
|
| Specialties, Surgical | 2 | 2013 | 144 | 0.190 |
Why?
|
| Republic of Korea | 1 | 2021 | 76 | 0.190 |
Why?
|
| Health Plan Implementation | 1 | 2021 | 91 | 0.190 |
Why?
|
| Guideline Adherence | 2 | 2021 | 654 | 0.190 |
Why?
|
| Neoplasm Metastasis | 10 | 2010 | 5250 | 0.180 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2020 | 31 | 0.180 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2002 | 882 | 0.180 |
Why?
|
| Perineum | 1 | 2021 | 111 | 0.180 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2013 | 285 | 0.180 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 552 | 0.170 |
Why?
|
| Linitis Plastica | 1 | 2019 | 12 | 0.170 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2023 | 433 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 7 | 2021 | 4064 | 0.170 |
Why?
|
| Survival Analysis | 20 | 2018 | 9311 | 0.170 |
Why?
|
| Splenectomy | 3 | 2007 | 167 | 0.170 |
Why?
|
| Indocyanine Green | 1 | 2020 | 128 | 0.170 |
Why?
|
| Pneumothorax | 1 | 2000 | 162 | 0.160 |
Why?
|
| Neoplasm Grading | 7 | 2017 | 1806 | 0.160 |
Why?
|
| Benchmarking | 1 | 2021 | 290 | 0.160 |
Why?
|
| Pyloric Antrum | 1 | 1999 | 60 | 0.160 |
Why?
|
| Gastrointestinal Motility | 1 | 1999 | 94 | 0.160 |
Why?
|
| Tumor Burden | 3 | 2015 | 2020 | 0.160 |
Why?
|
| Young Adult | 12 | 2023 | 22268 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2020 | 229 | 0.150 |
Why?
|
| Laparotomy | 3 | 2020 | 216 | 0.150 |
Why?
|
| Duodenum | 1 | 1999 | 155 | 0.150 |
Why?
|
| Abdominal Muscles | 1 | 1997 | 70 | 0.150 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1997 | 77 | 0.140 |
Why?
|
| Perioperative Care | 1 | 2021 | 448 | 0.140 |
Why?
|
| United States | 11 | 2019 | 16325 | 0.140 |
Why?
|
| Ultraviolet Rays | 4 | 2005 | 588 | 0.140 |
Why?
|
| Ultrasonography, Doppler | 1 | 1998 | 262 | 0.140 |
Why?
|
| Interferon-alpha | 5 | 2009 | 905 | 0.140 |
Why?
|
| Multivariate Analysis | 13 | 2018 | 4357 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 413 | 0.140 |
Why?
|
| Mucins | 3 | 2023 | 283 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2022 | 5431 | 0.140 |
Why?
|
| Medical Records | 2 | 2008 | 427 | 0.140 |
Why?
|
| Length of Stay | 3 | 2021 | 2048 | 0.140 |
Why?
|
| Polymorphism, Genetic | 4 | 2006 | 1425 | 0.140 |
Why?
|
| Heat-Shock Proteins | 2 | 2010 | 316 | 0.140 |
Why?
|
| Anastomotic Leak | 1 | 2017 | 86 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 1993 | 1011 | 0.140 |
Why?
|
| Cadherins | 3 | 2022 | 669 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2006 | 7982 | 0.140 |
Why?
|
| Radiotherapy | 5 | 2007 | 1852 | 0.130 |
Why?
|
| Proportional Hazards Models | 9 | 2020 | 5094 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2020 | 6269 | 0.130 |
Why?
|
| Radiation Dosage | 1 | 2020 | 1028 | 0.130 |
Why?
|
| Cardia | 1 | 2015 | 39 | 0.130 |
Why?
|
| Cancer Vaccines | 3 | 2010 | 733 | 0.130 |
Why?
|
| Adolescent | 29 | 2017 | 32464 | 0.130 |
Why?
|
| Gallbladder Neoplasms | 1 | 1997 | 248 | 0.130 |
Why?
|
| Insurance Coverage | 1 | 2018 | 273 | 0.130 |
Why?
|
| Social Support | 2 | 2016 | 575 | 0.120 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 348 | 0.120 |
Why?
|
| Diaphragm | 1 | 2016 | 186 | 0.120 |
Why?
|
| Microsatellite Instability | 2 | 2013 | 418 | 0.120 |
Why?
|
| Injections, Intraperitoneal | 3 | 2010 | 199 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 2 | 2005 | 1369 | 0.120 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 1061 | 0.120 |
Why?
|
| Soft Tissue Neoplasms | 4 | 2000 | 912 | 0.120 |
Why?
|
| Goblet Cells | 1 | 2015 | 132 | 0.120 |
Why?
|
| Quality of Health Care | 2 | 2018 | 643 | 0.120 |
Why?
|
| Morbidity | 1 | 2015 | 413 | 0.110 |
Why?
|
| Calcinosis | 1 | 2017 | 437 | 0.110 |
Why?
|
| Geriatric Assessment | 1 | 2015 | 288 | 0.110 |
Why?
|
| Incidence | 7 | 2020 | 5893 | 0.110 |
Why?
|
| Jejunostomy | 3 | 2020 | 54 | 0.110 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 3 | 2004 | 115 | 0.110 |
Why?
|
| Carcinoid Tumor | 1 | 2015 | 282 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 520 | 0.110 |
Why?
|
| Enteral Nutrition | 1 | 2015 | 337 | 0.110 |
Why?
|
| Cohort Studies | 8 | 2021 | 9466 | 0.100 |
Why?
|
| Interleukin-2 | 4 | 1998 | 851 | 0.100 |
Why?
|
| Neoplasm Seeding | 2 | 2005 | 66 | 0.100 |
Why?
|
| Propensity Score | 3 | 2021 | 794 | 0.100 |
Why?
|
| DNA Repair | 3 | 2006 | 1879 | 0.100 |
Why?
|
| Interferons | 2 | 2007 | 300 | 0.100 |
Why?
|
| Pancreaticojejunostomy | 1 | 1991 | 14 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 5 | 2003 | 5231 | 0.100 |
Why?
|
| Gastroscopy | 2 | 2002 | 144 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 662 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2021 | 1575 | 0.100 |
Why?
|
| Terminal Care | 1 | 2016 | 467 | 0.100 |
Why?
|
| Immunotoxins | 1 | 1991 | 117 | 0.090 |
Why?
|
| Leucovorin | 3 | 2023 | 340 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 795 | 0.090 |
Why?
|
| Surgical Wound Infection | 2 | 2013 | 471 | 0.090 |
Why?
|
| Databases, Factual | 4 | 2018 | 2314 | 0.090 |
Why?
|
| ErbB Receptors | 4 | 2015 | 2337 | 0.090 |
Why?
|
| Reoperation | 1 | 2016 | 1455 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 8 | 2007 | 5510 | 0.090 |
Why?
|
| Anastomosis, Surgical | 2 | 2023 | 376 | 0.090 |
Why?
|
| Age Factors | 6 | 2016 | 5498 | 0.090 |
Why?
|
| Radiotherapy Dosage | 5 | 2011 | 3984 | 0.090 |
Why?
|
| Cross-Over Studies | 3 | 2023 | 473 | 0.090 |
Why?
|
| Lymphatic Irradiation | 2 | 2008 | 139 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2023 | 8593 | 0.090 |
Why?
|
| Medical Oncology | 2 | 2024 | 1479 | 0.090 |
Why?
|
| Dacarbazine | 3 | 2009 | 490 | 0.090 |
Why?
|
| Colectomy | 3 | 2016 | 293 | 0.090 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 378 | 0.090 |
Why?
|
| Colonic Neoplasms | 4 | 2017 | 1424 | 0.090 |
Why?
|
| Caregivers | 1 | 2016 | 730 | 0.090 |
Why?
|
| Genetic Variation | 3 | 2006 | 2035 | 0.090 |
Why?
|
| Comorbidity | 1 | 2016 | 2447 | 0.090 |
Why?
|
| SEER Program | 3 | 2013 | 1028 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 1992 | 1024 | 0.090 |
Why?
|
| Anus Neoplasms | 2 | 2004 | 416 | 0.080 |
Why?
|
| Extremities | 2 | 2006 | 310 | 0.080 |
Why?
|
| Case-Control Studies | 9 | 2017 | 6034 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 5 | 2013 | 4458 | 0.080 |
Why?
|
| Disease Progression | 9 | 2017 | 6881 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 3 | 2004 | 1583 | 0.080 |
Why?
|
| Predictive Value of Tests | 6 | 2017 | 5015 | 0.080 |
Why?
|
| Consensus | 1 | 2013 | 1104 | 0.080 |
Why?
|
| Carcinoma, Lobular | 1 | 2012 | 619 | 0.080 |
Why?
|
| Endosonography | 4 | 2017 | 545 | 0.080 |
Why?
|
| Seroma | 1 | 2008 | 81 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2014 | 829 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2023 | 672 | 0.080 |
Why?
|
| Helicobacter pylori | 2 | 2017 | 1321 | 0.080 |
Why?
|
| Sepsis | 1 | 2013 | 668 | 0.080 |
Why?
|
| Pneumoperitoneum | 1 | 2007 | 17 | 0.080 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 138 | 0.070 |
Why?
|
| Gastroenterostomy | 1 | 2007 | 6 | 0.070 |
Why?
|
| Confidence Intervals | 4 | 2006 | 760 | 0.070 |
Why?
|
| Abdomen | 1 | 1999 | 338 | 0.070 |
Why?
|
| Child | 15 | 2011 | 30357 | 0.070 |
Why?
|
| Mitoxantrone | 1 | 2007 | 220 | 0.070 |
Why?
|
| Mucin-2 | 1 | 2007 | 56 | 0.070 |
Why?
|
| Helicobacter Infections | 1 | 2017 | 1245 | 0.070 |
Why?
|
| Hospitals, Urban | 1 | 2007 | 94 | 0.070 |
Why?
|
| Lymphocyte Activation | 2 | 1993 | 1699 | 0.070 |
Why?
|
| Hospitals, Teaching | 1 | 2007 | 124 | 0.070 |
Why?
|
| HLA-DQ Antigens | 2 | 1996 | 58 | 0.070 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2008 | 300 | 0.070 |
Why?
|
| Sarcoma | 4 | 2007 | 1831 | 0.070 |
Why?
|
| Nurses | 1 | 2007 | 84 | 0.070 |
Why?
|
| Nursing Staff, Hospital | 1 | 2007 | 71 | 0.070 |
Why?
|
| Radionuclide Imaging | 6 | 2004 | 658 | 0.070 |
Why?
|
| Tumor Necrosis Factors | 1 | 2006 | 35 | 0.070 |
Why?
|
| Appendectomy | 2 | 2018 | 130 | 0.070 |
Why?
|
| Immunologic Factors | 2 | 2008 | 665 | 0.070 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2006 | 65 | 0.070 |
Why?
|
| Capecitabine | 3 | 2015 | 391 | 0.070 |
Why?
|
| Induction Chemotherapy | 2 | 2024 | 672 | 0.070 |
Why?
|
| DNA-Binding Proteins | 4 | 2013 | 4893 | 0.070 |
Why?
|
| Receptors, Calcitriol | 1 | 2006 | 131 | 0.070 |
Why?
|
| Feasibility Studies | 5 | 2007 | 2371 | 0.070 |
Why?
|
| Apoptosis | 5 | 2007 | 7756 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 1999 | 533 | 0.070 |
Why?
|
| Chromatids | 1 | 2005 | 77 | 0.070 |
Why?
|
| Preoperative Period | 2 | 2018 | 346 | 0.060 |
Why?
|
| Neoplasm Proteins | 4 | 2005 | 3276 | 0.060 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2008 | 511 | 0.060 |
Why?
|
| Splenic Neoplasms | 1 | 2005 | 123 | 0.060 |
Why?
|
| Genes, p16 | 1 | 2005 | 131 | 0.060 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2007 | 215 | 0.060 |
Why?
|
| Bevacizumab | 2 | 2021 | 948 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2006 | 317 | 0.060 |
Why?
|
| Jejunum | 1 | 2005 | 228 | 0.060 |
Why?
|
| Survivors | 1 | 2010 | 1032 | 0.060 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2006 | 200 | 0.060 |
Why?
|
| Platelet Transfusion | 1 | 2004 | 162 | 0.060 |
Why?
|
| Biopsy | 8 | 2000 | 3502 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2017 | 7105 | 0.060 |
Why?
|
| Gastrostomy | 2 | 2020 | 189 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2012 | 1673 | 0.060 |
Why?
|
| Organophosphorus Compounds | 1 | 2004 | 104 | 0.060 |
Why?
|
| Arm | 2 | 2021 | 143 | 0.060 |
Why?
|
| Platelet Count | 1 | 2004 | 495 | 0.060 |
Why?
|
| Melphalan | 1 | 2006 | 839 | 0.060 |
Why?
|
| Sp1 Transcription Factor | 1 | 2004 | 190 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2007 | 642 | 0.060 |
Why?
|
| Odds Ratio | 5 | 2006 | 2302 | 0.050 |
Why?
|
| Arteries | 2 | 2017 | 283 | 0.050 |
Why?
|
| Rifampin | 1 | 2004 | 205 | 0.050 |
Why?
|
| Neuropilin-1 | 1 | 2003 | 40 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2388 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2004 | 275 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2006 | 597 | 0.050 |
Why?
|
| Survival | 1 | 2003 | 176 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 592 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2007 | 795 | 0.050 |
Why?
|
| Hemangiosarcoma | 1 | 2005 | 238 | 0.050 |
Why?
|
| Pilot Projects | 4 | 2008 | 2877 | 0.050 |
Why?
|
| Minocycline | 1 | 2004 | 187 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2006 | 1113 | 0.050 |
Why?
|
| Internationality | 2 | 2014 | 205 | 0.050 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2006 | 268 | 0.050 |
Why?
|
| Cetuximab | 2 | 2015 | 473 | 0.050 |
Why?
|
| CpG Islands | 1 | 2005 | 642 | 0.050 |
Why?
|
| Sodium Chloride | 1 | 2003 | 157 | 0.050 |
Why?
|
| Surgical Stapling | 1 | 2022 | 38 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2003 | 223 | 0.050 |
Why?
|
| Treatment Failure | 3 | 2008 | 1430 | 0.050 |
Why?
|
| HLA-DR Antigens | 1 | 2002 | 172 | 0.050 |
Why?
|
| Lymphokines | 1 | 2003 | 293 | 0.050 |
Why?
|
| Esophagus | 1 | 2005 | 560 | 0.050 |
Why?
|
| Micronutrients | 1 | 2022 | 74 | 0.050 |
Why?
|
| Mutation | 4 | 2013 | 15640 | 0.050 |
Why?
|
| Logistic Models | 4 | 2018 | 3487 | 0.050 |
Why?
|
| Ovarian Neoplasms | 3 | 2007 | 4720 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2005 | 524 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2002 | 163 | 0.050 |
Why?
|
| Suture Techniques | 2 | 2022 | 316 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 382 | 0.050 |
Why?
|
| Epirubicin | 1 | 2021 | 157 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 427 | 0.050 |
Why?
|
| Melanoma-Specific Antigens | 2 | 1991 | 84 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2023 | 312 | 0.050 |
Why?
|
| Radiopharmaceuticals | 2 | 2004 | 1333 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 266 | 0.050 |
Why?
|
| Thoracostomy | 1 | 2000 | 46 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 1581 | 0.050 |
Why?
|
| Pancreatic Fistula | 1 | 2021 | 99 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 4867 | 0.050 |
Why?
|
| Hematologic Neoplasms | 2 | 2004 | 1930 | 0.050 |
Why?
|
| Critical Care | 1 | 2007 | 796 | 0.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2011 | 2129 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 5121 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2017 | 4793 | 0.040 |
Why?
|
| Morphine | 1 | 2022 | 320 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2008 | 2099 | 0.040 |
Why?
|
| Gastric Mucosa | 2 | 2020 | 624 | 0.040 |
Why?
|
| Skin | 1 | 2005 | 1280 | 0.040 |
Why?
|
| Antigens, Neoplasm | 3 | 1991 | 1561 | 0.040 |
Why?
|
| DNA Methylation | 2 | 2013 | 2729 | 0.040 |
Why?
|
| Time Factors | 9 | 2015 | 13261 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2007 | 923 | 0.040 |
Why?
|
| Clinical Trials as Topic | 3 | 2010 | 3838 | 0.040 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 1999 | 15 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 671 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 4 | 2008 | 980 | 0.040 |
Why?
|
| Quinazolines | 1 | 2004 | 934 | 0.040 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2013 | 200 | 0.040 |
Why?
|
| Piperazines | 1 | 2008 | 2143 | 0.040 |
Why?
|
| Vinblastine | 3 | 2009 | 460 | 0.040 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 10641 | 0.040 |
Why?
|
| Lymphoscintigraphy | 1 | 1999 | 35 | 0.040 |
Why?
|
| Cefonicid | 1 | 1998 | 2 | 0.040 |
Why?
|
| Manometry | 1 | 1999 | 77 | 0.040 |
Why?
|
| Piperidines | 1 | 2004 | 1066 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2005 | 959 | 0.040 |
Why?
|
| Bacteremia | 1 | 2004 | 694 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 1998 | 689 | 0.040 |
Why?
|
| DNA Primers | 3 | 2008 | 1413 | 0.040 |
Why?
|
| Lipid A | 1 | 1998 | 31 | 0.040 |
Why?
|
| Cytokines | 2 | 2001 | 2870 | 0.040 |
Why?
|
| Catheterization | 1 | 2000 | 436 | 0.040 |
Why?
|
| Celiac Artery | 1 | 2018 | 41 | 0.040 |
Why?
|
| Splenic Artery | 1 | 2018 | 50 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2002 | 1164 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2002 | 671 | 0.040 |
Why?
|
| Chi-Square Distribution | 3 | 2013 | 1348 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2007 | 3962 | 0.040 |
Why?
|
| Recombinant Proteins | 4 | 2009 | 2934 | 0.040 |
Why?
|
| Drug Administration Schedule | 5 | 2005 | 3512 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2018 | 226 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2006 | 5495 | 0.040 |
Why?
|
| Cephalosporins | 1 | 1998 | 159 | 0.040 |
Why?
|
| Immunohistochemistry | 5 | 2013 | 7711 | 0.040 |
Why?
|
| Stomach | 1 | 2020 | 393 | 0.040 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2021 | 702 | 0.040 |
Why?
|
| Surgical Instruments | 1 | 1997 | 141 | 0.040 |
Why?
|
| Rectal Neoplasms | 2 | 2002 | 1241 | 0.040 |
Why?
|
| Alleles | 4 | 2006 | 2398 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2021 | 683 | 0.040 |
Why?
|
| Hepatic Artery | 1 | 2018 | 251 | 0.040 |
Why?
|
| Etoposide | 1 | 1999 | 888 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 1072 | 0.030 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1998 | 209 | 0.030 |
Why?
|
| Genes, MHC Class II | 1 | 1996 | 66 | 0.030 |
Why?
|
| Axilla | 3 | 2008 | 922 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 3376 | 0.030 |
Why?
|
| Animals | 10 | 2010 | 61175 | 0.030 |
Why?
|
| Rural Health Services | 1 | 2016 | 38 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2022 | 653 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2000 | 589 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2007 | 7456 | 0.030 |
Why?
|
| Health Status | 1 | 2019 | 610 | 0.030 |
Why?
|
| United Kingdom | 1 | 2016 | 274 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2008 | 3636 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 2 | 2013 | 260 | 0.030 |
Why?
|
| Home Care Services | 1 | 2016 | 98 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 1998 | 525 | 0.030 |
Why?
|
| Liver | 1 | 2005 | 2993 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 225 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 1996 | 278 | 0.030 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2015 | 87 | 0.030 |
Why?
|
| Carcinoma, Small Cell | 1 | 1997 | 416 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2020 | 1050 | 0.030 |
Why?
|
| Cyclosporine | 1 | 1996 | 284 | 0.030 |
Why?
|
| DNA Damage | 1 | 2003 | 1983 | 0.030 |
Why?
|
| Sunlight | 2 | 2006 | 78 | 0.030 |
Why?
|
| Asepsis | 1 | 1994 | 5 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2015 | 229 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2000 | 1238 | 0.030 |
Why?
|
| CA-19-9 Antigen | 1 | 2015 | 149 | 0.030 |
Why?
|
| Pelvis | 2 | 2007 | 378 | 0.030 |
Why?
|
| Day Care, Medical | 1 | 2013 | 14 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 1998 | 701 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 842 | 0.030 |
Why?
|
| Chromosome Disorders | 1 | 1996 | 417 | 0.030 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2013 | 50 | 0.030 |
Why?
|
| Deoxycytidine | 2 | 2011 | 1375 | 0.030 |
Why?
|
| Genotype | 3 | 2006 | 4015 | 0.030 |
Why?
|
| Intraoperative Period | 2 | 2006 | 254 | 0.030 |
Why?
|
| Celecoxib | 1 | 2013 | 205 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2013 | 73 | 0.030 |
Why?
|
| Nuclear Proteins | 3 | 2013 | 3362 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2015 | 348 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 108 | 0.030 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2013 | 174 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 634 | 0.030 |
Why?
|
| Phosphatidylethanolamines | 1 | 1993 | 63 | 0.030 |
Why?
|
| Acetylmuramyl-Alanyl-Isoglutamine | 1 | 1993 | 58 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2013 | 1464 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 9065 | 0.030 |
Why?
|
| Clinical Protocols | 2 | 1995 | 471 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 3098 | 0.030 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 2192 | 0.030 |
Why?
|
| Thoracic Neoplasms | 1 | 2015 | 343 | 0.030 |
Why?
|
| Registries | 1 | 2000 | 2300 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 1437 | 0.030 |
Why?
|
| Keratins | 2 | 2004 | 337 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2013 | 237 | 0.030 |
Why?
|
| Gastric Bypass | 1 | 2013 | 95 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2012 | 1403 | 0.020 |
Why?
|
| Cell Division | 3 | 2004 | 2555 | 0.020 |
Why?
|
| Central Venous Catheters | 1 | 2013 | 100 | 0.020 |
Why?
|
| Physicians | 1 | 2000 | 912 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1991 | 181 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 3119 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 1994 | 452 | 0.020 |
Why?
|
| Rosaniline Dyes | 2 | 2004 | 109 | 0.020 |
Why?
|
| Remission Induction | 3 | 2008 | 3622 | 0.020 |
Why?
|
| Dehydration | 1 | 2011 | 89 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 492 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1997 | 1615 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2008 | 2304 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 3621 | 0.020 |
Why?
|
| Decision Trees | 1 | 1991 | 177 | 0.020 |
Why?
|
| Weight Loss | 1 | 2015 | 650 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2013 | 439 | 0.020 |
Why?
|
| Observer Variation | 1 | 2013 | 713 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2018 | 929 | 0.020 |
Why?
|
| Anorexia | 1 | 2011 | 147 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 165 | 0.020 |
Why?
|
| Immunotherapy | 2 | 2010 | 3518 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 1991 | 145 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2015 | 600 | 0.020 |
Why?
|
| Point Mutation | 2 | 2003 | 777 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 1994 | 486 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 1547 | 0.020 |
Why?
|
| Marital Status | 1 | 2010 | 98 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1991 | 292 | 0.020 |
Why?
|
| CD3 Complex | 1 | 1991 | 321 | 0.020 |
Why?
|
| Recurrence | 4 | 2000 | 4889 | 0.020 |
Why?
|
| Nausea | 1 | 2011 | 537 | 0.020 |
Why?
|
| Catheter-Related Infections | 1 | 2013 | 272 | 0.020 |
Why?
|
| Base Sequence | 2 | 2008 | 4903 | 0.020 |
Why?
|
| Databases as Topic | 2 | 2000 | 140 | 0.020 |
Why?
|
| Cross Infection | 1 | 1994 | 550 | 0.020 |
Why?
|
| ras Proteins | 1 | 2013 | 784 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2013 | 751 | 0.020 |
Why?
|
| Risk | 2 | 2006 | 1942 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 1996 | 1977 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 1991 | 385 | 0.020 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1971 | 415 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 463 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 1725 | 0.020 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2008 | 26 | 0.020 |
Why?
|
| Coronary Artery Bypass | 2 | 2000 | 753 | 0.020 |
Why?
|
| Mice, Nude | 3 | 2004 | 4341 | 0.020 |
Why?
|
| Groin | 1 | 2008 | 78 | 0.020 |
Why?
|
| Family | 1 | 2012 | 745 | 0.020 |
Why?
|
| Tissue Adhesives | 1 | 2008 | 51 | 0.020 |
Why?
|
| Suction | 1 | 2008 | 109 | 0.020 |
Why?
|
| Phenotype | 2 | 2013 | 6353 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 16073 | 0.020 |
Why?
|
| Taxoids | 1 | 2011 | 992 | 0.020 |
Why?
|
| Endothelial Cells | 2 | 2004 | 1078 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2008 | 219 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2004 | 3594 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2005 | 1631 | 0.020 |
Why?
|
| Pneumonia | 1 | 2013 | 765 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 2298 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 1991 | 1398 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 3218 | 0.020 |
Why?
|
| Injections, Intradermal | 1 | 2007 | 57 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 1710 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 707 | 0.020 |
Why?
|
| Thoracic Arteries | 1 | 1986 | 10 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2013 | 848 | 0.020 |
Why?
|
| Body Mass Index | 1 | 1994 | 2281 | 0.020 |
Why?
|
| Adrenalectomy | 1 | 2008 | 194 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2006 | 70 | 0.020 |
Why?
|
| Liposomes | 2 | 2003 | 700 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1379 | 0.020 |
Why?
|
| HLA-DQ beta-Chains | 2 | 1996 | 31 | 0.020 |
Why?
|
| Markov Chains | 1 | 2007 | 181 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2007 | 204 | 0.020 |
Why?
|
| Physical Examination | 1 | 2008 | 299 | 0.020 |
Why?
|
| Disease Management | 1 | 2012 | 1118 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2006 | 63 | 0.020 |
Why?
|
| Thrombosis | 1 | 2013 | 808 | 0.020 |
Why?
|
| Clinical Competence | 1 | 1994 | 1368 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 1331 | 0.020 |
Why?
|
| Mammary Arteries | 1 | 1986 | 64 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2017 | 4182 | 0.020 |
Why?
|
| Sunburn | 1 | 2005 | 34 | 0.020 |
Why?
|
| Pathology, Surgical | 1 | 2006 | 87 | 0.020 |
Why?
|
| Vascular Patency | 1 | 1986 | 222 | 0.020 |
Why?
|
| Endonucleases | 1 | 2006 | 179 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2004 | 2649 | 0.020 |
Why?
|
| Skin Ulcer | 1 | 2006 | 78 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2006 | 152 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2004 | 4887 | 0.020 |
Why?
|
| Mass Screening | 1 | 1994 | 1572 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2006 | 236 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2006 | 168 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 3399 | 0.020 |
Why?
|
| Blood Specimen Collection | 1 | 1985 | 94 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2006 | 427 | 0.020 |
Why?
|
| Heart | 1 | 2011 | 1261 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2006 | 230 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2013 | 1532 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 2198 | 0.020 |
Why?
|
| Silicones | 1 | 2004 | 56 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 2717 | 0.010 |
Why?
|
| Capillaries | 1 | 2004 | 102 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2008 | 6181 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1991 | 1168 | 0.010 |
Why?
|
| Infusions, Intravenous | 2 | 1998 | 1414 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2013 | 1900 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 2564 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2007 | 611 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 745 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 558 | 0.010 |
Why?
|
| Brain | 1 | 2017 | 4219 | 0.010 |
Why?
|
| Emotions | 1 | 2008 | 578 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 1690 | 0.010 |
Why?
|
| Endometrial Stromal Tumors | 1 | 2003 | 7 | 0.010 |
Why?
|
| Pericytes | 1 | 2004 | 97 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2006 | 307 | 0.010 |
Why?
|
| Radiography | 1 | 2008 | 1936 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2007 | 679 | 0.010 |
Why?
|
| Technetium | 1 | 2003 | 77 | 0.010 |
Why?
|
| Wound Healing | 2 | 1986 | 829 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2008 | 475 | 0.010 |
Why?
|
| Lymphoma | 2 | 2004 | 1489 | 0.010 |
Why?
|
| Immunoglobulin G | 2 | 1998 | 1065 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 533 | 0.010 |
Why?
|
| Minority Groups | 1 | 2005 | 330 | 0.010 |
Why?
|
| Age of Onset | 1 | 2005 | 808 | 0.010 |
Why?
|
| Benzamides | 1 | 2008 | 1876 | 0.010 |
Why?
|
| Kidney | 1 | 2011 | 2201 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2003 | 238 | 0.010 |
Why?
|
| Child, Preschool | 3 | 2011 | 16882 | 0.010 |
Why?
|
| Ascites | 1 | 2003 | 210 | 0.010 |
Why?
|
| HLA-DRB1 Chains | 1 | 2002 | 80 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 697 | 0.010 |
Why?
|
| Codon | 1 | 2002 | 241 | 0.010 |
Why?
|
| Age Distribution | 1 | 2003 | 712 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 1182 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2003 | 718 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2003 | 907 | 0.010 |
Why?
|
| Folic Acid | 1 | 2004 | 364 | 0.010 |
Why?
|
| Lymphedema | 1 | 2004 | 250 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 2342 | 0.010 |
Why?
|
| Homozygote | 1 | 2003 | 734 | 0.010 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1991 | 1907 | 0.010 |
Why?
|
| Dogs | 3 | 1986 | 1173 | 0.010 |
Why?
|
| Washington | 1 | 2000 | 75 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 5021 | 0.010 |
Why?
|
| Information Services | 1 | 2000 | 49 | 0.010 |
Why?
|
| Random Allocation | 1 | 2002 | 714 | 0.010 |
Why?
|
| Edema | 1 | 2002 | 269 | 0.010 |
Why?
|
| Models, Organizational | 1 | 2000 | 75 | 0.010 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 362 | 0.010 |
Why?
|
| Mice | 4 | 2004 | 35455 | 0.010 |
Why?
|
| Sentinel Surveillance | 1 | 1999 | 35 | 0.010 |
Why?
|
| Pain | 1 | 2008 | 1689 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2004 | 876 | 0.010 |
Why?
|
| Melanoma, Amelanotic | 1 | 1998 | 9 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2005 | 1916 | 0.010 |
Why?
|
| Surgical Mesh | 1 | 1980 | 206 | 0.010 |
Why?
|
| Thorax | 1 | 2000 | 219 | 0.010 |
Why?
|
| Immunity, Active | 1 | 1998 | 14 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 1999 | 246 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1995 | 1928 | 0.010 |
Why?
|
| Diarrhea | 1 | 2002 | 697 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1998 | 104 | 0.010 |
Why?
|
| Safety | 1 | 1999 | 472 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1999 | 299 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1998 | 281 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 990 | 0.010 |
Why?
|
| Data Collection | 1 | 2000 | 642 | 0.010 |
Why?
|
| Leadership | 1 | 2000 | 275 | 0.010 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2000 | 294 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 1475 | 0.010 |
Why?
|
| Professional Staff Committees | 1 | 1997 | 30 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 11638 | 0.010 |
Why?
|
| Infant | 2 | 2011 | 13889 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 1269 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 1799 | 0.010 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 1996 | 23 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2005 | 1355 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 3660 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2005 | 2032 | 0.010 |
Why?
|
| Dextropropoxyphene | 1 | 1996 | 7 | 0.010 |
Why?
|
| Cimetidine | 1 | 1996 | 28 | 0.010 |
Why?
|
| Diphenhydramine | 1 | 1996 | 20 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1996 | 259 | 0.010 |
Why?
|
| Proto-Oncogenes | 1 | 1996 | 201 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1998 | 632 | 0.010 |
Why?
|
| Leukemia | 1 | 2004 | 1673 | 0.010 |
Why?
|
| Premedication | 1 | 1996 | 133 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 5952 | 0.010 |
Why?
|
| Fatigue | 1 | 2002 | 1267 | 0.010 |
Why?
|
| X Chromosome | 1 | 1996 | 341 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1996 | 224 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1999 | 1583 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1996 | 315 | 0.010 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1996 | 314 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 1980 | 668 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1996 | 400 | 0.010 |
Why?
|
| Karyotyping | 1 | 1996 | 1030 | 0.010 |
Why?
|
| Gloves, Surgical | 1 | 1994 | 11 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1996 | 1125 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1996 | 745 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1996 | 1502 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 6221 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1996 | 1433 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2006 | 5360 | 0.010 |
Why?
|
| Aorta, Thoracic | 2 | 1980 | 573 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1992 | 174 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1992 | 173 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2002 | 4462 | 0.010 |
Why?
|
| Popliteal Artery | 1 | 1971 | 54 | 0.010 |
Why?
|
| HLA-A2 Antigen | 1 | 1992 | 170 | 0.010 |
Why?
|
| Axillary Artery | 1 | 1971 | 34 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2004 | 7333 | 0.010 |
Why?
|
| Surface Properties | 1 | 1971 | 185 | 0.010 |
Why?
|
| Subclavian Artery | 1 | 1971 | 82 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1993 | 332 | 0.010 |
Why?
|
| Autopsy | 1 | 1971 | 180 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2004 | 3096 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1996 | 1472 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1996 | 1477 | 0.010 |
Why?
|
| Femoral Artery | 1 | 1971 | 222 | 0.010 |
Why?
|
| Polymers | 1 | 1971 | 229 | 0.010 |
Why?
|
| Cattle | 1 | 1971 | 800 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 1980 | 1764 | 0.010 |
Why?
|
| Monocytes | 1 | 1993 | 785 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2004 | 4921 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1991 | 1090 | 0.000 |
Why?
|
| Prosthesis Design | 1 | 1971 | 794 | 0.000 |
Why?
|
| Gene Expression | 1 | 1996 | 3574 | 0.000 |
Why?
|
| Neoplasm Transplantation | 1 | 1991 | 1533 | 0.000 |
Why?
|
| Aorta | 1 | 1971 | 707 | 0.000 |
Why?
|
| Swine | 1 | 1971 | 1610 | 0.000 |
Why?
|
| Jugular Veins | 1 | 1986 | 111 | 0.000 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1986 | 124 | 0.000 |
Why?
|
| Saphenous Vein | 1 | 1986 | 99 | 0.000 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1992 | 1296 | 0.000 |
Why?
|
| Carotid Arteries | 1 | 1986 | 256 | 0.000 |
Why?
|
| Bone Neoplasms | 1 | 1998 | 2657 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2003 | 12145 | 0.000 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 1996 | 5298 | 0.000 |
Why?
|
| Coronary Vessels | 1 | 1986 | 693 | 0.000 |
Why?
|
| Polyethylene Terephthalates | 1 | 1980 | 42 | 0.000 |
Why?
|
| Heart Septal Defects | 1 | 1980 | 51 | 0.000 |
Why?
|
| Iliac Artery | 1 | 1980 | 109 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1986 | 1521 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1980 | 233 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1980 | 618 | 0.000 |
Why?
|